September 29, 2024-October 1, 2024
Hero background

Event Session

Terminal Disclaimers, Continuations, and the False Thicket Narrative *

September 29, 2024 @ 5:30 PM EST – Salon 4

5:30 PM ET
September 29, 2024

Salon 4

Terminal Disclaimers, Continuations, and the False Thicket Narrative *

View Session Speakers

CLEErroneous attempts to blame patents for high drug prices is continuing unabated, with the Administration and courts making it harder to obtain and keep sufficient patent protection for even life-saving, breakthrough drugs. Witness the U.S. Patent and Trademark Office (USPTO) Notice of Proposed Rulemaking (NPRM) from May 10, 2024 (89 Fed. Reg. 40439), that would dramatically alter patent applicant and patentee statutory rights in their patent filings by proposing a change to the requirements for submission of a terminal disclaimer (TD). In summary, the proposed rule would require that every TD include a provision agreeing that the patent with the TD is unenforceable if at least one claim of the underlying patent has been finally held unpatentable or invalid under Sections 102 or 103. The USPTO is also preparing to dramatically increase the fee for filing a terminal disclaimer, and despite being under an injunction prohibiting any attempt to curtail continuation practice, the USPTO is poised to similarly and dramatically increase the fees associated with filing a continuation. Meanwhile, courts more aggressively using prosecution laches to find patents unenforceable if prosecution lasts longer than six (6) years. What can the industry do to prepare for these changes? Will the rules and fees be challenged in court? Why does the false patent thicket narrative continue to have traction and influence government policy and action?

Materials

Survey

https://www.surveymonkey.com/r/Terminal-Disclaimers-Continuations-and-the-False-Thicket-Narrative



Add to Calendar 12/09/2025 12:45 PM America/New_York Terminal Disclaimers, Continuations, and the False Thicket Narrative *

Erroneous attempts to blame patents for high drug prices is continuing unabated, with the Administration and courts making it harder to obtain and keep sufficient patent protection for even life-saving, breakthrough drugs. Witness the U.S. Patent and Trademark Office (USPTO) Notice of Proposed Rulemaking (NPRM) from May 10, 2024 (89 Fed. Reg. 40439), that would dramatically alter patent applicant and…

Session Speakers

Henry Hadad

Henry Hadad

Senior Vice President and Deputy General Counsel

Bristol-Myers Squibb

Sherry Knowles

Principal

Knowles Intellectual Property Strategies

John Miller

Senior Corporate Counsel

Pfizer

Gene Quinn

President & CEO

IPWatchdog, Inc.